COVID-19 | Pfizer will request authorization to administer its vaccine to children between 5 and 12 years of age in the United States.

Pfizer and BioNTech announced Tuesday that they released initial data on the results of the vaccine against COVID-19 in children between 5 and 12 years old to the US authorities and said that in the coming weeks they plan to formally request its emergency use for this group.

SIGHT: COVID-19 | Pfizer booster dose increased antibody levels 20 times in Sinovac vaccinated

In a statement, the pharmaceutical companies indicated that they have shared the data from phase 2/3 of their clinical trial with the US Food and Drug Administration, after recently disclosing that two low doses of the vaccine generated an immune response ” robust ”in children.

Based on initial data, based on testing of nearly 2,300 children ages 5 to 12, a two-dose 10-microgram regimen of the product had one that had been immunized with two 30-microgram doses in the overall study.

SIGHT: Delta Plus variant of the coronavirus: More contagious and resistant to vaccines?

The request for emergency use in the US for this age group will be made “In the next weeks”, while firms have and other regulators, according to the note.

Pfizer and BioNTech also said they plan to submit the data from the phase 3 trial to a scientific peer review later.

SIGHT: COVID-19 | Results of the Sinopharm clinical trial conducted in Peru will be “very soon”

The vaccine from these pharmaceutical companies, which is one of the most widely distributed worldwide, has been available to adults 12 years of age and older in the US since May and

The companies said they expect to have immunity and safety data for two other younger age groups, 6 months to 2 years, and 2 to 5 years, as early as the fourth quarter of this year.

Although children are less susceptible to developing severe symptoms of COVID-19, they can spread the virus and the situation has become dire for vulnerable people with the face-to-face return to schools of millions of children in the country.

• COVID-19 | Pfizer booster dose increased antibody levels 20 times in Sinovac vaccinated
• Pfizer Starts Human Trials of Messenger RNA Flu Vaccine
• Delta Plus variant of the coronavirus: More contagious and resistant to vaccines?
• COVID-19 | Patients who come to the ICU are mostly men and have more antibodies
• COVID-19 | Results of the Sinopharm clinical trial conducted in Peru will be “very soon”
• Sinopharm will be accepted to travel to the US: reasons to trust the Chinese vaccine
• What are “rogue” antibodies and what do they have to do with severe COVID-19?
• What will the third year of the pandemic be like ?, by Elmer Huerta
• COVID-19 | New Chinese vaccine is 79% effective against Delta variant
• COVID-19 May Look Like a Cold in the Future, AstraZeneca Developer Says
• Delta variant of COVID-19 is now predominant in Peru: five things you should know
• COVID-19 | Europe will decide in October whether to authorize Pfizer’s booster dose
• Sinopharm will be accepted to travel to the US: reasons to trust the Chinese vaccine
• COVID-19 | How close are we to the end of the pandemic?
• Who will the third dose of Pfizer reach in the US?
• COVID-19 infection may precede Guillain-Barré syndrome in rare cases
• COVID-19 | “It is a harm to public health for someone to apply more than two doses on their own”
• COVID-19 | Six billion doses of vaccines have been administered worldwide
• They find a virus very similar to that of COVID-19 in bats of Laos
• Brazil and Argentina will produce mRNA vaccines against COVID-19 for the region, PAHO announces
• Convalescent Plasma: Does This Therapy Work To Treat COVID-19 Patients?

Follow us on twitter:

!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);

.

Deshawn